PRKACA for Fibrolamellar hepatocellular carcinoma

PRKACA 治疗纤维板层肝细胞癌

• 批准号: 9554490
• 负责人: Anton Simeonov
• 金额: $ 4.47万
• 依托单位: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9554490
• 关键词: Biological Assay; Biology; Catalytic Domain; Chemicals; Chimera organism; Code; Collaborations; Communities; Cyclic AMP-Dependent Protein Kinases; Development; Disease; Evaluation; Extramural Activities; Fibrolamellar Hepatocellular Carcinoma; Fostering; General Population; Genomics; Goals; Homologous Gene; Informatics; Lead; Liver; Liver diseases; Malignant Neoplasms; Malignant neoplasm of liver; Modeling; Molecular Chaperones; PRKACA gene; Pathogenesis; Patients; Pharmaceutical Chemistry; Pharmaceutical Preparations; Phenotype; Process; Proteins; Publications; Recording of previous events; Research; Research Personnel; Resources; Sampling; Synthesis Chemistry; Teenagers; Testing; Therapeutic; Transcript; United States National Institutes of Health; Validation; Work; assay development; base; drug development; drug discovery; high throughput screening; human disease; improved; new technology; novel therapeutics; screening; small molecule; small molecule inhibitor; small molecule therapeutics; therapeutic development; tool; tumor; young adult

During this period, the NCGC has identify and develop potential assays to enable high-throughput screening. As a center, the NCGC has fostered and maintained over 130 active collaborations with both NIH and extramural investigators, facilitating drug discovery efforts across the entire spectrum of human disease. These efforts have led to dozens of high-throughput screens and a number of medicinal chemistry campaigns to further improve on screening hits, providing our collaborators and the general research community with publications and a variety of promising small molecule probes and leads. In addition, the NCGC has worked to advance a number of informatic initiatives to make better use of existing drug and disease target information and provide the general public with easily accessible resources, further catalyzing the development of new therapies for human disease.

在此期间，NCGC识别并开发了潜在测定，以实现高通量筛查。 作为一个中心，NCGC与NIH和壁外研究人员培养并维持了130多次主动合作，从而促进了整个人类疾病范围内的药物发现工作。这些努力导致了数十个高通量屏幕和许多药物化学运动，以进一步改善筛选效果，为我们的合作者和一般研究社区提供出版物以及各种有希望的小分子探测器和铅。此外，NCGC努力促进许多信息计划，以更好地利用现有的药物和疾病目标信息，并为公众提供易于获得的资源，从而进一步促进针对人类疾病的新疗法的发展。